New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Wednesday, November 11, 2026

Back to the front page

ON THE TAPE with Guy Adami

Guy Adami discusses Nvidia, Anthropic's IPO prospects, energy, gold and the AI trade.

NVDA $4.6T
WHAT ARE WE DOING? “Contrarians At The Gate” 2 clicks

From X

@aleabitoreddit

Serenity on X

Yes, I still like and will defend $AAOI despite the "shitco" claims from the level 1 NPCs on X: - AOI recently signed a $1B to $1.5B 3Y contract with a hyperscalers - Majority of people missed this part, but there's another $5-$7B contract expected to be signed in weeks. This is very large scale relative to current valuations, and gives AOI more visibility for the future. However, the risk I see here is that hyperscalers prefer CPO/NPO laser procurement over pluggables. So that's probably part of the reason they're not doing pre-payments or take/pay like they would for $LITE or $MU capacity expansion. - There's only single digits amount of companies in the world that probably have 300mW-400mW CPO laser capabilities (one of which is the "shitco") This was also a large reason why $COHR got $20B agreements, $LITE $5B agreements + $NVDA investments (UHP lasers). I'd argue they should focus on merchant high end lasers than using their own capacity toward 800g pluggables. And just source lasers from merchant market That would change their valuation premiums overnight IMO, given they have a lot of optionality from end-to-end supply chain manufacturing. _ In terms of valuations, they deserved to be compressed from their infinite $600M ATMs that they used earlier (that they now stopped abusing). And since timelines slipped a few months from DSP bottlenecks and equipment procurement/installation. Then you have macro overhang too + overall AI selloff. As for the operational side of things, it's not eternity and relatively out of their hands... but I wouldn't conflate it as failing qualifications or facing order cancellations. Building up US supply chains like $INTC is always going to be more difficult than easy-mode Asia manufacturing in Malaysia as well. I'd argue this same execution risk they're being punished for over in Texas (like Intel foundry), will turn into a premium once US capacity scales into revenue
@aleabitoreddit

Serenity on X

Not always right on timing, but I'm pretty confident long term they'll play out. Just look at $AXTI, everyone thought it was a dead company last year and InP substrates were a commodity. -> Q4 2025 gross margins: 20.9% -> Q1 2026: 29.6% -> Q2 2026: 44.9% -> Q3 2026: 56.0% -> Q4 2026: 60%+ est. With legacy memory like $ESMT, I did guess earnings correctly, they made a whopping $331M+ net income relative to $1.9B MC But stock still dropped somehow... but eventually as time passes out I'm personally confident majority will play out directionally right.
@aleabitoreddit

Serenity on X

This aged pretty well, when I said this last year in 2025, Clickhouse was a $6.7B company... Now as an update, their secondary valuation sits around ~$50B, which $NBIS owns 25%+ of. I've always liked Nebius the most because sum of parts, with all their lesser known subsidiaries growing alongside their core neocloud business. Including Avride (self-driving), Clickhouse, Toloka, and other subsidiaries that they owned. This year Nebius also acquired: - Tavily (web search and retrival) - Clarifai (Inference orchestration) Which scale independently as well (the others were integrated into Nebius Token Factory). Hard to view $NBIS as just another neocloud when it has billions in scaling value outside its core infrastructure business.
@KEDM_COM

KEDM.com on X

In June, Alphabet $GOOGL surprised the market by announcing the mother of all equity raises. The plan was to raise $80 billion, consisting of $15b in convertible preferred stock and $25b in common stock, followed by a $40b ATM set to start in Q3. The official reason was to fund AI Capex and pay taxes on employee stock compensation. The timing seemed obvious … they wanted to get ahead of a liquidity crunch as SpaceX $SPCX, OpenAI, and Anthropic lined up their IPOs. SpaceX went public in June, and Anthropic’s November IPO could raise up to $64.4b, with shares expected to start trading on Nasdaq as $ANT on November 19. We recently wrote about how the typical IPO underperforms by ~20% on a 3-year horizon. This effect was more pronounced when companies were unprofitable, resulting in an average underperformance of 30%. Companies like $SPCX are not set up for patient buy-and-hold investors. Index providers waived the profitability requirement and cut the seasoning window from 90 days to 5. Passive investors will be forced to buy shares just after the initial IPO pump, and just before the accelerated unlock. There’s a 200-year history of finance bros dumping on retail. SpaceX simply figured out how to do it at scale.

Investor Letters

All letters

Cat-Scratch Fervo

Fervo Energy raised $2 billion in its May IPO, then fell nearly 70% below issue price after a Morpheus short report, despite targeting 1 GW…

FRVO $2.3B
Doomberg 4 clicks

Sea Ltd Earnings Update: Q3 2026

Sea Ltd reported Q3 2026 revenue of $8.6 billion, up 43.4% year over year, while net income rose 34.0%.

SE $48B
SixSigmaCapital: Navigating the Financial Markets 4 clicks
OKLO · short

Oklo INC

Oklo is framed as a portfolio basket short and a concept company that could become a compounding short.

OKLO $4.1B
Value Investors Club

TSOH Weekly Roundup (08/28/2026)

TSOH Weekly Roundup tracks Dick’s Sporting Goods’ Foot Locker setback and Brown-Forman’s internal debate over a potential Pernod Ricard…

DKS $13B
TSOH Investment Research

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 83 of 283

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

375 firms

Sectors

Ordered by how often our editor reaches for them.